Brief: Inhibikase Therapeutics Initiates Development Of Second Generation C-Abl Inhibitors And Names Ikt-148009 As Risvodetinib
21/08/2023 13:33
Aug 21 (Reuters) -
* INHIBIKASE THERAPEUTICS INITIATES DEVELOPMENT OF SECOND
GENERATION C-ABL INHIBITORS AND NAMES IKT-148009 AS RISVODETINIB
Source text for Eikon: ID:nPn82gt2Pa
Further company coverage: IKT.O
((reuters.briefs@thomsonreuters.com))
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Appoints Scott Wasserman To Board Of Directors
Inhibikase Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Inhibikase Q2 net loss widens on higher R&D, SG&A costs
Inhibikase Therapeutics, Inc. expected to post a loss of 11 cents a share - Earnings Preview
Brief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share